Promis Neurosciences Inc.
PMNPromis Neurosciences Inc. in brief
Promis Neurosciences Inc. is a listed company in the Biotechnology industry, based in Canada. Its market value was $100 M on 30 October 2026, which makes it the 18,728th largest listed company in the world and the 705th largest in Canada on this site. Neil K. Warma is its chief executive. Its shares trade under the symbol PMN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Promis Neurosciences Inc.
ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer’s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS’ technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or artificial intelligence. We believe this platform provides a potential advantage by selectively targeting the toxic misfolded proteins with therapeutics.
From the company's annual report filed with the US SEC: read the report
Promis Neurosciences Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- ✎Renamed ProMIS Neurosciences Inc.Formerly Amorfix Life Sciences Ltd.
Events of Promis Neurosciences Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Canada: #961 (Jan 2022) · #839 (Dec 2022) · #828 (Jul 2023) · #893 (Jan 2024) · #48 (Mar 2026) · #492 (Aug 2026) · #782 (Oct 2026) · #705 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -17.1%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 113.7%
- Net debt
- $-13M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-40M | $-40M | — |
| Dec 2024 | — | — | $-17M | $3M | — |
| Dec 2023 | — | — | $-14M | $-13M | — |
| Dec 2022 | — | — | $-23M | $-18M | — |
| Dec 2021 | — | — | $-8M | $-10M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-28M | — | — | $-22.61 | — |
| Dec 2024 | $-27M | — | — | $2.63 | — |
| Dec 2023 | $-11M | — | — | $-1.07 | — |
| Dec 2022 | $-17M | $0M | $-17M | $-2.41 | — |
| Dec 2021 | $-9M | $0M | $-9M | $-1.69 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 28, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 20, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 9, 2026DEF 14AProxy statement
- Mar 25, 202610-KAnnual report · period to Dec 2025
- Mar 25, 20268-KCurrent reportResults of operations
Official filings of Promis Neurosciences Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-40 M
- Net income
- $-40 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $9 M
- Total liabilities
- $10 M
- Total equity
- $-1 M
As of December-2025
Top 31 institutional investors in Promis Neurosciences Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 1,292,657 | — | 14.37% | $14 M | Nov 16, 2026 |
| 2 | Deep Track Capital, LP | 740,117 | -95,538 (-11.43%) | 8.23% | $8 M | Nov 16, 2026 |
| 3 | Wellington Management Group LLP | 696,378 | 0 (0.00%) | 7.74% | $8 M | Nov 16, 2026 |
| 4 | Ally Bridge Group (NY) LLC | 620,319 | 0 (0.00%) | 6.89% | $7 M | Nov 16, 2026 |
| 5 | Adage Capital Partners GP, L.L.C. | 564,275 | +400,000 (+243.49%) | 6.27% | $6 M | Nov 16, 2026 |
| 6 | Trails Edge Capital Partners, LP | 557,103 | 0 (0.00%) | 6.19% | $6 M | Nov 16, 2026 |
| 7 | Yu Fan | 329,760 | 0 (0.00%) | 3.67% | $4 M | Nov 16, 2026 |
| 8 | Woodline Partners LP | 314,601 | -127,310 (-28.81%) | 3.50% | $3 M | Nov 16, 2026 |
| 9 | Sphera Funds Management LTD. | 254,782 | -70,809 (-21.75%) | 2.83% | $3 M | Nov 16, 2026 |
| 10 | 683 Capital Management, LLC | 250,000 | +155,000 (+163.16%) | 2.78% | $3 M | Nov 16, 2026 |
| 11 | Ikarian Capital, LLC | 205,000 | 0 (0.00%) | 2.28% | $2 M | Nov 16, 2026 |
| 12 | Ameriprise Financial Inc | 185,700 | 0 (0.00%) | 2.06% | $2 M | Nov 16, 2026 |
| 13 | Millennium Management LLC | 121,123 | +65,078 (+116.12%) | 1.35% | $1 M | Nov 16, 2026 |
| 14 | ADAR1 Capital Management, LLC | 92,850 | 0 (0.00%) | 1.03% | $1 M | Nov 16, 2026 |
| 15 | Boothbay Fund Management, LLC | 62,078 | 0 (0.00%) | 0.69% | $1 M | Nov 16, 2026 |
| 16 | Citadel Advisors LLC | 22,902 | New | 0.25% | $0 M | Nov 16, 2026 |
| 17 | Two Sigma Investments, LP | 16,228 | New | 0.18% | $0 M | Nov 16, 2026 |
| 18 | Jane Street Group, LLC | 14,621 | New | 0.16% | $0 M | Nov 12, 2026 |
| 19 | Quadrature Capital Ltd | 11,615 | New | 0.13% | $0 M | Nov 13, 2026 |
| 20 | Seven Fleet Capital Management LP | 10,600 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 21 | Morgan Stanley | 7,559 | 0 (0.00%) | 0.08% | $0 M | Nov 13, 2026 |
| 22 | Osaic Holdings, Inc. | 360 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 23 | Jpmorgan Chase & Co | 285 | New | 0.00% | $0 M | Nov 12, 2026 |
| 24 | Royal Bank Of Canada | 218 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 25 | Steward Partners Investment Advisory, LLC | 94 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Show all 31: investors 26 to 31
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Tower Research Capital LLC (TRC) | 33 | New | 0.00% | $0 M | Nov 16, 2026 |
| 27 | Caitong International Asset Management Co., Ltd | 10 | +7 (+233.33%) | 0.00% | $0 M | Oct 29, 2026 |
| 28 | Federation des caisses Desjardins du Quebec | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 29 | TD Waterhouse Canada Inc. | 5 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 30 | National Bank Of Canada /fi/ | 2 | New | 0.00% | $0 M | Nov 16, 2026 |
| 31 | UBS Group AG | 1 | -690 (-99.86%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Promis Neurosciences Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 5,676 | $0 M | — | <0.01% | +1550% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Promis Neurosciences Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Eugene WilliamsDirector | Buy | +26,500 | $3.430 | $91 K | 40,213 | Form 4 |
| filed | Neil CashmanChief Scientific Officer, Director | Buy | +10,000 | $3.860 | $39 K | 14,532 | Form 4 |
| filed | Eugene WilliamsDirector | Buy | +1,316 | $3.990 | $5 K | 13,713 | Form 4 |
| filed | Johanne KaplanChief Development Officer | Buy | +2,280 | $13.30 | $30 K | 6,221 | Form 4 |
| filed | Patrick D. KirwinDirector | Buyindirect | +4,000 | $11.33 | $45 K | 4,653 | Form 4 |
| filed | Eugene WilliamsDirector | Buy | +2,000 | $24.40 | $49 K | 12,397 | Form 4 |
| filed | Eugene WilliamsDirector | Buy | +2,000 | $24.00 | $48 K | 10,397 | Form 4 |
| filed | Eugene WilliamsDirector | Buy | +1,000 | $21.89 | $22 K | 8,397 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Promis Neurosciences Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2,500 reverse split
Trading halts
- 2026-11-02 14:40 UTC, code LUDP, resumed 14:45 UTC
- 2026-11-02 14:31 UTC, code LUDP, resumed 14:36 UTC
- 2026-10-30 16:12 UTC, code LUDP, resumed 16:22 UTC
- 2026-01-30 15:09 UTC, code LUDP, resumed 15:14 UTC
- 2026-01-30 14:33 UTC, code LUDP, resumed 14:38 UTC
Fails to deliver
- : 102 shares at $11.08
- : 3,398 shares at $9.68
- : 465 shares at $8.05
- : 62 shares at $8.34
- : 908 shares at $8.29
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Promis Neurosciences Inc. scorecard#
Passes 0 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-17.1%Free cash flow is -17.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-22.61 vs 2.63Diluted EPS -22.61 in fiscal 2025 against 2.63 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$40 MNet income -$40 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.9×Current ratio 0.88 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year66.1%Diluted shares up 66.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Promis Neurosciences Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | 33+214%— | 11+34.9%— | 7.9−51.0%— | 16+248%— | 4.6—— | |
| General and administrative | 6.8+9.7%— | 6.2−3.0%— | 6.4−12.5%— | 7.3+99.1%— | 3.7—— | |
| Operating expenses | 40+139%— | 17+18.0%— | 14−39.0%— | 23+182%— | 8.3—— | |
| Operating income | −40—— | −17—— | −14—— | −23—— | −8.3—— | |
| Interest expense and finance costs | — | — | — | 0.3−32.2%— | 0.4—— | |
| Other non-operating income (expense) | 0.4−97.7%— | 20+1767%— | 1.1−80.2%— | 5.3—— | −1.5—— | |
| Income tax | — | 0—— | 0—— | 0—— | — | |
| Net income including minority interests | −40−1529%— | 2.8—— | −13—— | −18—— | −9.8—— | |
| Net income attributable to shareholders | −40−1529%— | 2.8—— | −13—— | −18—— | −9.8—— | |
| Earnings per share, basic | -22.61−944%— | 2.68r0.11—— | -1.07—— | -2.41—— | -1.69—— | |
| Earnings per share, diluted | -22.61−960%— | 2.63r0.11—— | -1.07—— | -2.41—— | -1.69—— | |
| Shares, weighted average (basic) | 1.8+69.4%— | 1.0r26−91.6%— | 12+63.8%— | 7.5+29.7%— | 5.8—— | |
| Shares, weighted average (diluted) | 1.8+66.0%— | 1.1r26−91.4%— | 12+63.8%— | 7.5+29.7%— | 5.8—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 6.1−54.0%66.6% | 13+5.5%70.3% | 13+114%92.5% | 5.9−65.3%84.9% | 17—95.5% | |
| Short-term investments | 0.0+2.1%0.4% | 0.0+2.1%0.2% | 0.0+4.4%0.2% | 0.0−6.7%0.4% | 0.0—0.2% | |
| Other current assets | 3.0−45.7%33.0% | 5.6+465%29.5% | 1.0−0.8%7.3% | 1.0+35.2%14.4% | 0.7—4.2% | |
| Current assets | 9.2−51.4%100% | 19+38.9%100% | 14+97.3%100% | 6.9−61.0%99.7% | 18—99.8% | |
| Property, plant and equipment | — | — | — | 0.0−93.1%0.0% | 0.0—0.0% | |
| Other intangible assets | — | — | — | 0.0−24.5%0.3% | 0.0—0.2% | |
| Total assets | 9.2−51.4%100% | 19+38.9%100% | 14+96.7%100% | 6.9−61.0%100% | 18—100% | |
| Accounts payable | 2.5+46.4%27.7% | 1.7−77.8%9.2% | 7.8+164%57.6% | 3.0+628%43.0% | 0.4—2.3% | |
| Current liabilities | 10+369%113% | 2.2−76.3%11.7% | 9.3+45.8%68.7% | 6.4+590%92.6% | 0.9—5.2% | |
| Total liabilities | 10+331%114% | 2.4−75.4%12.8% | 9.9+19.3%72.4% | 8.3−31.6%119% | 12—68.1% | |
| Retained earnings | −130—−1420% | −91—−480% | −93—−686% | −80—−1159% | −62—−350% | |
| Shareholders' equity | −1.3−108%−13.7% | 16+339%87.2% | 3.8—27.6% | −1.3−124%−19.5% | 5.7—31.9% | |
| Total liabilities and equity | 9.2−51.4%100% | 19+38.9%100% | 14+96.7%100% | 6.9−61.0%100% | 18—100% | |
| Shares outstanding | 2.2+64.6%— | 1.3r33−93.1%— | 19+120%— | 8.6+19.2%— | 7.2—— | |
| Cash-flow statement | ||||||
| Share-based compensation | 0.9+3.9%— | 0.8+204%— | 0.3−44.3%— | 0.5−5.4%— | 0.5—— | |
| Cash from operating activities | −28—— | −27—— | −11—— | −17—— | −9.3—— | |
| Capital expenditure | — | — | — | −0.0—— | −0.0—— | |
| Cash from investing activities | −0.0—— | −0.0—— | −0.0—— | −0.0−102%— | 0.1—— | |
| Shares issued | 0.7+272%— | 0.2—— | — | 5.0−68.7%— | 16—— | |
| Cash from financing activities | 21−24.9%— | 28+57.1%— | 18+173%— | 6.5−74.6%— | 26—— | |
| Change in cash | −7.2−1135%— | 0.7−89.7%— | 6.7—— | −11−169%— | 16—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 33+14.9%— | 6.7−31.5%— | 9.5+8.8%— | 7.0+27.6%— | 9.4*+117%— | 9.8+282%— | 8.7+438%— | 5.5+157%— | 4.3*+94.4%— | 2.6—— | 1.6—— | 2.1—— | 2.2*—— | |
| General and administrative | 7.7+9.4%— | 1.9−2.4%— | 2.7+91.3%— | 1.7−16.1%— | 1.4*−16.3%— | 2.0+4.4%— | 1.4+31.9%— | 2.0+28.5%— | 1.7*+1.7%— | 1.9—— | 1.1—— | 1.6—— | 1.6*—— | |
| Operating expenses | 40+13.8%— | 8.6−26.7%— | 12+20.4%— | 8.6+15.9%— | 11*+79.5%— | 12+165%— | 10+275%— | 7.5+103%— | 6.0*+54.9%— | 4.4—— | 2.7—— | 3.7—— | 3.9*—— | |
| Operating income | −40—— | −8.6—— | −12—— | −8.6—— | −11*—— | −12—— | −10—— | −7.5—— | −6.0*—— | −4.4—— | −2.7—— | −3.7—— | −3.9*—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | 0.0*—— | — | 0.1—— | — | |
| Other non-operating income (expense) | 1.5−75.6%— | 0.5+166%— | 0.5+694%— | 0.4+257%— | 0.1*−98.3%— | 0.2−98.8%— | 0.1−24.9%— | 0.1+170%— | 5.8*+1859%— | 14—— | 0.1—— | 0.0—— | 0.3*—— | |
| Net income including minority interests | −39—— | −8.2*—— | −12*—— | −8.2—— | −11*—— | −12*−225%— | −10*—— | −7.3—— | −0.2*—— | 9.3*—— | −2.6*—— | −3.6—— | −3.6*—— | |
| Net income attributable to shareholders | −39—— | −8.2—— | −12—— | −8.2—— | −11*—— | −12−225%— | −10—— | −7.3—— | −0.2*—— | 9.3—— | −2.6—— | −3.6—— | −3.6*—— | |
| Earnings per share, basic | — | -0.89—— | -1.28—— | -1.26—— | — | -5.93r-0.24−2013%— | -7.26r-0.29—— | -5.27r-0.21—— | — | 0.31—— | -0.13—— | -0.19—— | — | |
| Earnings per share, diluted | — | -0.89—— | -1.28—— | -1.26—— | — | -5.93r-0.24−2013%— | -7.26r-0.29—— | -5.27r-0.21—— | — | 0.31—— | -0.13—— | -0.19—— | — | |
| Shares, weighted average (basic) | 9.1+368%— | 9.1+368%— | 9.1+556%— | 6.5+368%— | — | 2.0r49−93.5%— | 1.4r35−92.9%— | 1.4r35−92.9%— | — | 30—— | 20—— | 20—— | — | |
| Shares, weighted average (diluted) | 9.1+368%— | 9.1+368%— | 9.1+556%— | 6.5+368%— | — | 2.0r49−93.5%— | 1.4r35−92.9%— | 1.4r35−92.9%— | — | 30—— | 20—— | 20—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 44—93.5% | 44+186%93.5% | 53+1085%94.2% | 64+663%94.7% | 6.1−54.0%66.6% | 15−28.5%71.8% | 4.5+354%47.4% | 8.4+235%61.3% | 13+5.5%70.3% | 22—87.9% | 1.0—70.4% | 2.5—70.4% | 13—92.5% | |
| Short-term investments | 0.0—0.1% | 0.0+2.1%0.1% | 0.0+2.1%0.1% | 0.0+2.1%0.1% | 0.0+2.1%0.4% | 0.0+2.1%0.2% | 0.0+2.1%0.3% | 0.0+2.1%0.2% | 0.0+2.1%0.2% | 0.0—0.1% | 0.0—2.3% | 0.0—0.9% | 0.0—0.2% | |
| Other current assets | 3.1—6.5% | 3.1−49.3%6.5% | 3.2−34.9%5.7% | 1.8−66.4%2.6% | 3.0−45.7%33.0% | 6.0+105%28.1% | 5.0+1191%52.2% | 5.2+415%38.5% | 5.6+465%29.5% | 2.9—12.0% | 0.4—27.3% | 1.0—28.7% | 1.0—7.3% | |
| Current assets | 47—100% | 47+120%100% | 57+496%100% | 66+381%97.3% | 9.2−51.4%100% | 21−12.5%100% | 9.5+575%100% | 14+285%100% | 19+38.9%100% | 25—100% | 1.4—100% | 3.5—100% | 14—100% | |
| Total assets | 47—100% | 47+120%100% | 57+496%100% | 67+394%100% | 9.2−51.4%100% | 21−12.5%100% | 9.5+575%100% | 14+285%100% | 19+38.9%100% | 25—100% | 1.4—100% | 3.5—100% | 14—100% | |
| Accounts payable | 0.5—1.0% | 0.5−88.5%1.0% | 1.8−35.5%3.2% | 1.7+43.0%2.5% | 2.5+46.4%27.7% | 4.2+167%19.6% | 2.8+38.0%29.2% | 1.2−14.5%8.8% | 1.7−77.8%9.2% | 1.6—6.4% | 2.0—143% | 1.4—39.6% | 7.8—57.6% | |
| Current liabilities | 5.3—11.3% | 5.3−56.2%11.3% | 7.2−26.5%12.7% | 6.6+63.1%9.8% | 10+369%113% | 12+363%56.9% | 9.8+210%103% | 4.1+53.3%29.7% | 2.2−76.3%11.7% | 2.6—10.8% | 3.2—225% | 2.6—74.6% | 9.3—68.7% | |
| Total liabilities | 5.4—11.4% | 5.4−56.0%11.4% | 7.3−26.3%12.9% | 6.7+60.3%9.9% | 10+331%114% | 12−28.8%57.2% | 9.9+168%104% | 4.2+20.3%30.6% | 2.4−75.4%12.8% | 17—70.3% | 3.7—262% | 3.5—97.8% | 9.9—72.4% | |
| Retained earnings | −159—−336% | −159—−336% | −150—−265% | −139—−206% | −130—−1420% | −120—−558% | −108—−1137% | −98—−718% | −91—−480% | −90—−369% | −100—−7075% | −97—−2737% | −93—−686% | |
| Shareholders' equity | 42—88.6% | 42+355%88.6% | 49—87.1% | 61r61+541%90.1% | −1.3−108%−13.7% | 9.2+26.3%42.8% | −0.4r−0.4—−4.0% | 9.5+12185%69.4% | 16+339%87.2% | 7.3—29.7% | −2.3—−162% | 0.1—2.2% | 3.8—27.6% | |
| Total liabilities and equity | 47—100% | 47+120%100% | 57+496%100% | 67+394%100% | 9.2−51.4%100% | 21−12.5%100% | 9.5+575%100% | 14+285%100% | 19+38.9%100% | 25—100% | 1.4—100% | 3.5—100% | 14—100% | |
| Shares outstanding | 9.0—— | 9.0−83.3%— | 9.0−72.6%— | 9.0−72.6%— | 2.2+64.6%— | 54+64.6%— | 33+72.4%— | 33+72.4%— | 1.3r33−93.1%— | 33—— | 19—— | 19—— | 19—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 1.3+0.5%— | 0.5+145%— | 0.4+92.9%— | 0.2−22.8%— | 0.2*−67.4%— | 0.2+62.9%— | 0.2+1078%— | 0.2+286%— | 0.6*+12773%— | 0.1—— | 0.0—— | 0.1—— | 0.0*—— | |
| Cash from operating activities | −41—— | −9.4*—— | −10*—— | −12—— | −9.3*—— | −10*—— | −3.9*—— | −4.9—— | −8.7*—— | −6.7*—— | −1.5*—— | −10—— | −3.8*—— | |
| Shares issued | — | — | — | — | 0*—— | — | — | — | 0*—— | 0*—— | 0*—— | 0.2—— | — | |
| Cash from financing activities | 70—— | 0.0*—— | 0*—— | 70—— | −0.0*−100%— | — | — | — | 0.5*—— | 27*—— | 0*—— | 0.2—— | −0.5*—— | |
| Change in cash | 29—— | −9.4*−186%— | −10*—— | 58—— | −9.3*—— | 11*−47.0%— | −3.9*—— | −4.9—— | −8.2*—— | 21*—— | −1.5*—— | −10—— | −4.3*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Promis Neurosciences Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Promis Neurosciences Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 5 · Material agreement 5 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2022 | $7 M | No. 4 | $2 to $10 million | 23 | equity, options | SEC |
| Aug 2021 | $18 M | No. 3 | $10 to $50 million | 34 | equity, options | SEC |
| Mar 2021 | $7 M | No. 2 | $2 to $10 million | 7 | equity, debt, options | SEC |
| Apr 2018 | $2 M | No. 1 | Under $2 million | 18 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Promis Neurosciences Inc. compares in Biotechnology
- Market cap$100 M · higher than 36% of 726
- FCF yield-17.1% · higher than 47% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Promis Neurosciences Inc.🇨🇦 | $100 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Promis Neurosciences Inc.? Verify and update this profile — free
Show Promis Neurosciences Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.